final program.qxd - Parallels Plesk Panel

PP 5.9
Chronic HBV infection associated with opisthorchiasis: efficacy of antiviral therapy
Kulagina Olga, Kulagina Kristina
Department of Infectious Diseases, Kemerovo State Medical Academy, Kemerovo,
Russia. Student, Kemerovo State Medical Academy,Kemerovo, Russia.
Background
Chronic infection caused by Opisthorchis felineus (O.f.) is relatively common in Western
Syberia (Russia). Moreover, 14% of the chronic HBV infections are associated with
opisthorchiasis in this region. Opisthorchiasis might cause marked immunosuppression
and lead to the antiviral treatment failure. In our study we assessed efficacy of
antiretroviral therapy in patients with chronic HBV/O.f. co-infection.
Methods
In total 70 patients experiencing chronic HBV infection were involved into the study. Thirty
five patients with chronic HBV/O.f. co-infection constituted the case group, while 35
patients without opisthorchiasis served as a control. In both groups at baseline HBV
infection had signs of replication stage and moderate activity. All patients were prescribed
lamivudine, 100 mg orally daily for 48 weeks. Treatment outcomes were assessed by
blood testing for HBV DNA at 6 and 12 months after 48 weeks of therapy. Outcome
variables were measured by proportions and Pearson chi-square test was applied to
assess their differences between groups.
Results
A sustained virologic response (HBV/DNA negative at 12 months after 48 weeks of
therapy with lamivudine) was achieved in 35 (50%) patients. In the case group fewer
patients had a sustained virologic response than those in the control group, however,
these differences were not statistically significant (respectively 14 (40%) and 21 (60%),
p=0.09). A transitory virologic response (HBV/DNA negative at 6 months, but HBV/DNA
positive at 12 months after 48 weeks of therapy) was observed in 18 (25.7%) patients. A
response rate of 20% was seen in patients from the case group and of 31.4% in patients
served as a control (p=0.27).
Conclusions
We recorded a negative trend of antiviral treatment outcomes in patients with chronic
HBV/O.f. co-infection. The problem needs to be studied more profoundly; absence of
statistically significant differences between groups might be due to small number of our
observations
“ Focusing FIRST on PEOPLE “ 216 w w w . i s h e i d . c o m